SAT0423 LONG-TERM SURVIVAL OF THE FIRST BIOLOGIC TREATMENT IN PSORIATIC ARTHRITIS AND THE EFFECT OF THE SELECTED TREATMENT ON DRUG SURVIVAL; TURKBIO REGISTRY. (2nd June 2020)

• Record Type: Journal Article
• Authors: Kocaer, S. B.; Yüce İnel, T.; Erez, Y.; Köken Avşar, A.; Uslu, S.; Karakas, A.; Gulle, S.; Can, G.; Sari, İ.; Birlik, M.; Dalkiliç, E.; Pehlivan, Y.; Akar, S.; Cefle, A.; Öztürk, M. A.; Yolbaş, S.; Yilmaz, N.; Erten, S.; Akkoc, N.; Onen, F.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 1165
• Page End: 1166
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.3909
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Currently, biologic treatments are used effectively in patients with psoriatic arthritis (PsA). Objectives: The aim of this study was to evaluate and compare long-term drug survival of the first biologic treatments including adalimumab, certolizumab, etanercept, golimumab, infliximab, secukinumab and ustekinumab in patients with PsA. Methods: PsA patients, electronically registered at each visit in the TURKBIO database between 2011 and 2019 were included in the study. PASW 18.0 for Windows was used for statistical analysis. Drug survival rates were calculated by Kaplan Meier method. Results: 355 patients (227 women; axial PsA = 48, peripheral PsA = 307) were included in the study (Table 1 ). Adalimumab was the most commonly used first biologic treatment (n=125; 37.6%). The rate of drug survival was found to be 0.75 at month 60 in patients receiving the first biologic treatment (Figure 1 ). There was no significant difference in drug survival rate between tumor necrosis factor alpha inhibitor (TNFi) and non-TNFi biologic drugs (p=0.56). No difference was also found in drug survival rates between each biologic treatment. Conclusion: The results of this study establish that more than half of patients with PsA can remain in their initial biologic treatment over a long term. It has been observed that the choice of biologic treatment did not effect the drug survival in PsA. Disclosure of Interests: None declared